Analysts have estimated that combined global sales of monoclonal antibody biopharmaceuticals will approach US$125 billion by 2020. Around 50 monoclonal antibody biologics have been approved in the United States and Europe for the treatment of range of serious diseases. A significant portion of the biopharmaceutical industry’s new product pipeline is comprised of monoclonal antibodies that are in the discovery or clinical manufacturing phases and the market for therapeutic monoclonal antibodies is becoming increasingly competitive. Ensuring commercial success In order to attract additional rounds of investment for future commercialization activities, biopharmaceutical companies must progress their candidates through process development and into …